FDA hears input on psychedelics, PDUFA, lung cancer's next-gen therapies boost survival

The FDA held a public forum to discuss the future of psychedelic therapeutics and a meeting on recommendations for reauthorizing the Prescription Drug User Fee Act (PDUFA) following the launch of its TrialBlazer initiative. Definium Therapeutics achieved a late-stage trial success with its LSD drug, while Novartis faces challenges after setbacks with three assets.

This Wire brief sits within Fusion42's coverage of Biotech.